mHealth Spot

Isomorphic Labs raises $5bn, and it still hasn’t dosed a patient

Investors have now put more than $7bn into a company that has not yet started a human trial. That is the striking fact behind Isomorphic Labs’ new $5bn Series C, which arrives just six months after its $2.1bn Series B.

The round was co-led by Greenoaks and Sequoia. Andreessen Horowitz, Thrive Capital, Alphabet, GV, CapitalG, Temasek and the Sovereign AI fund also took part. Isomorphic is headquartered in London and was spun out of Google DeepMind. Demis Hassabis founded it and serves as CEO.

What Isomorphic is building

The company’s foundation is software developed at DeepMind, including AlphaFold, the protein structure prediction system that earned a Nobel Prize. On top of that, Isomorphic has built a proprietary drug design engine called IsoDDE and a pipeline of therapeutic candidates designed with AI. Its research focuses on cancer and immune disorders.

The company says the new money will go toward three things: advancing IsoDDE, building more capable AI models to push into new areas of biology, and developing the infrastructure needed to take candidates into clinical trials. It is also assembling a partner ecosystem to deepen understanding of the mechanisms behind disease.

What the leadership is claiming

Hassabis said the company’s drug design engines are generating molecules with “unprecedented precision and speed.” Max Jaderberg, Isomorphic’s president, said the teams make repeatable scientific advances every week, and that mixing machine learning researchers with experienced drug hunters is solving biological problems that have stalled traditional research for decades.

These are bold statements, and the company has not published data in this announcement to back them. Better molecular profiles are a meaningful step. But a molecule that looks good in silico still has to survive toxicology, dosing studies and, above all, efficacy in patients.

Why the clinic is the real test

Drug development has a brutal attrition rate. Most candidates that enter human trials never reach approval, and the process typically takes a decade or more. AI’s pitch is that better early design should mean fewer failures later and a faster path to the clinic. That case is plausible. It is not yet proven, and no AI-designed drug has so far completed the journey to approval.

That is why the timing of this round matters. Isomorphic says it is moving its first programs toward clinical trials. Once those begin, the field will finally get evidence on whether AI-native discovery changes outcomes, not just speed.

The bigger picture

The scale of the funding says as much about investor appetite as it does about Isomorphic. Capital is flowing to AI companies at historic levels, and drug discovery is one of the few areas where a clear technical success, AlphaFold, already exists. Alphabet’s participation, through three separate investment arms, also signals that the parent company sees this as a long-term commitment.

For clinicians and health entrepreneurs, the practical takeaway is to watch the trial pipeline, not the funding headlines. Cancer and immune disorders are crowded, high-stakes areas, and early clinical readouts will show whether this money buys better medicines or simply faster molecules.

Exit mobile version